

Clinical Policy: Attention Deficit Hyperactivity Disorder Assessment and Treatment

Reference Number: TX.CP.MP.124

Effective Date: 08/16

Last Review Date: 12/17

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders in children and also occurs with an increasing prevalence of diagnosis in adults. ADHD affects the cognitive, academic, emotional, and social well-being of individuals and can persist throughout life. While there is no single test to diagnose ADHD, a clinical assessment based on defined clinical parameters establishes criteria for diagnosis in children and adults.

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® that the following services for the assessment and treatment of ADHD are **medically necessary**:
 - A. Assessment
 1. Complete medical evaluation with history and physical examination;
 2. Parent/child interview or patient interview, if adult, to obtain information listed in Diagnostic and Statistical Manual of Mental Health Disorders, Fifth Edition (DSM-5);
 3. Complete psychiatric evaluation or other services provided by a psychiatrist, psychologist, or other behavioral health professional;
 4. Laboratory evaluation prior to stimulant medication therapy, including any of the following:
 - a. Complete blood count;
 - b. Liver function tests;
 - c. Cardiac evaluation and screening incorporating an electrocardiogram (ECG);
 5. Measurement of thyroid hormone levels if patient exhibits clinical manifestations of hyperthyroidism;
 6. Assessment of comorbid behavioral health and/or medical diagnoses and associated symptoms;
 7. When not otherwise excluded, other services for the assessment of ADHD to meet the DSM-5 criteria.
 - B. Treatment:
 1. Pharmacotherapy;
 2. Behavioral modification;
 3. Treatment of comorbid behavioral health and/or medical diagnoses and associated symptoms;
 4. When not otherwise excluded, other services for the treatment of ADHD.
- II. It is the policy of health plans affiliated with Centene Corporation that the following services for the assessment and treatment of ADHD are **investigational or unproven** (may not be all-inclusive):

CLINICAL POLICY

Attention Deficit Hyperactivity Disorder

A. Assessment:

1. Actimeter
2. Computerized electroencephalogram (EEG)
3. Computerized Tests of Attention and Vigilance
4. Education and achievement testing
5. Electronystagmography in the absence of symptoms of vertigo or balance dysfunction
6. Event-related potentials
7. Functional near-infrared spectroscopy
8. Hair analysis
9. IgG blood tests
10. Measurement of zinc
11. Neuroimaging (e.g., CT [computed tomography], CAT [computerized axial tomography], MRI [magnetic resonance imaging], including diffusion tensor imaging), MRS (magnetic resonance spectroscopy), PET (positron emission tomography), and SPECT (single-photon emission computerized tomography)
12. Neuropsychiatric EEG-based assessment aid system
13. Neuropsychologic testing for suspected uncomplicated cases of ADHD (without history of head trauma, seizures)
14. Physical performance testing
15. Otoacoustic emissions in the absence of signs of hearing loss
16. Quotient ADHD system / test
17. Synaptosomal-associated protein (SNAP) 25 gene polymorphisms testing
18. Transcranial magnetic stimulation – evoked measures (e.g., short-interval cortical inhibition in motor cortex) as a marker of ADHD symptoms
19. Tympanometry in the absence of hearing loss
20. Vestibular and balance function

B. Treatment:

1. Acupuncture/acupressure
2. Anti-*candida albicans* medication
3. Anti-fungal medication
4. Anti-motion sickness medication
5. Auditory Integration Therapy
6. Applied kinesiology
7. Brain integration
8. Chelation
9. Chiropractic manipulation
10. Cognitive behavior modification
11. Cognitive rehabilitation
12. Computerized training on working memory
13. Deep pressure sensory vest
14. Dietary counseling and treatments, i.e., Feingold diet
15. Dore program / dyslexia – dyspraxia attention treatment (DDAT)
16. Educational intervention (e.g., classroom environmental manipulation, academic skills training, and parental training)
17. EEG biofeedback

CLINICAL POLICY

Attention Deficit Hyperactivity Disorder

18. Herbal remedies
19. Homeopathy
20. Intensive behavioral intervention programs
21. Megavitamin therapy
22. Metronome training
23. Mineral supplementation
24. Music therapy
25. Optometric vision training
26. Psychopharmaceuticals (lithium, benzodiazepines, and selective serotonin reuptake inhibitors, unless the patient also exhibits anxiety and depression)
27. Reboxetine
28. Self-care management training
29. Sensory integration therapy
30. The Good Vibrations Device
31. The Neuro Emotional Technique
32. Therapeutic eurythmy (movement therapy)
33. Transcranial magnetic stimulation / cranial electric stimulation
34. Yayarin
35. Vision therapy
36. Yoga

Background

ADHD is among the most commonly diagnosed neurodevelopmental disorders in children and adolescents and is increasingly being diagnosed in adults. The main characteristics of ADHD are symptoms of inattention, hyperactivity, and impulsivity that have continued for at least six months and are maladaptive and inconsistent with development level.¹ There is no single genetic or behavioral test to diagnose ADHD. Instead a clinical diagnosis based on the *Diagnostic and Statistical Manual of Mental Disorders-5* (DSM-V) criteria is applicable for both children and adults.² The prevalence of adult ADHD has been estimated to be around 4.4% in the United States and 3.4% internationally, whereas the prevalence in children and adolescents ranges from 2 –18%.^{2,3}

In 2011, the American Academy of Pediatrics (AAP) published a clinical practice guideline to clarify the diagnosis, evaluation, and treatment parameters of ADHD.⁴ This guideline expanded the age range of children to include preschool aged children and adolescents and suggests an expanded scope for behavioral interventions.⁴ The evaluation of comorbid conditions that might coexist with ADHD must also be considered.⁴ Similar clinical recommendations have been made by various organizations for adults, including the Canadian ADHD Resource Alliance, the American Academy of the Child and Adolescent Psychiatry, the National Institutes of Health, and the British Association for Psychopharmacology.⁵ Pharmacotherapy can provide a way to manage ADHD symptoms and improve quality of life.

Stimulants and non-stimulants are common examples of medications prescribed to treat ADHD. Chan, *et al*, performed a systemic review of sixteen randomized clinical trials and one meta-analysis that involved 2668 participants and evaluated pharmacological and psychosocial treatments of ADHD in adolescents aged 12 years to 18 years. They found that extended-release

CLINICAL POLICY

Attention Deficit Hyperactivity Disorder

methylphenidate and amphetamine formulations, atomoxetine, and extended-release guanfacine led to clinically significant symptom reduction.⁶

While the pathogenesis of ADHD is unknown, the clinical impairments in neurobehavioral and neurodevelopmental functioning pathways elicit deficiencies in vigilance, perceptual-motor speed, working memory, verbal learning, and response inhibition.² Consequently ADHD affects the cognitive, academic, emotional, and social wellbeing of individuals and can persist throughout life.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2017, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT codes considered not medically necessary when billed with a sole diagnosis of ADHD

CPT® Codes	Description
70450	Computed tomography, head or brain; without contrast material
70551	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material
70553	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences
76390	Magnetic resonance spectroscopy
78607	Brain imaging tomographic (SPECT)
78608	Brain imaging, positron emission tomography (PET); metabolic evaluation.
78609	Brain imaging, positron emission tomography (PET); perfusion evaluation
81229	Cytogenetic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities
82365	Infrared spectroscopy
82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
82787	Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each
84630	Zinc
86001	Allergen specific IgG quantitative or semiquantitative, each allergen
92065	Orthoptic and/or pleoptic training, with continuing medical direction and evaluation
90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management

CLINICAL POLICY
Attention Deficit Hyperactivity Disorder

CPT® Codes	Description
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management
90901	Biofeedback training by any modality
92540	Basic vestibular evaluation, includes spontaneous nystagmus test with eccentric gaze fixation nystagmus, with recording, positional nystagmus test, minimum of 4 positions, with recording, 5ptokinetic nystagmus test, bidirectional foveal and peripheral stimulation, with recording, and oscillating tracking test, with recording
92541	Spontaneous nystagmus test, including gaze and fixation nystagmus, with recording
92542	Positional nystagmus test, minimum of 4 positions, with recording
92544	Optokinetic nystagmus test, bidirectional, foveal or peripheral stimulation, with recording
92545	Oscillating tracking test, with recording
92548	Computerized dynamic posturography
92550	Tympanometry and reflex threshold measurements
92558	Evoked otoacoustic emissions, screening (qualitative measurement of distortion product or transient evoked otoacoustic emissions), automated analysis
92567	Tympanometry (impedance testing)
92585	Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; comprehensive
92586	Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; limited
92587	Distortion product evoked otoacoustic emissions; limited evaluation (to confirm the presence or absence of hearing disorder, 3-6 frequencies) or transient evoked otoacoustic emissions, with interpretation and report
92588	Distortion product evoked otoacoustic emissions; comprehensive diagnostic evaluation (quantitative analysis of outer hair cell function by cochlear mapping, minimum of 12 frequencies), with interpretation and report
95803	Actigraphy testing recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)
95812	Electroencephalogram (EEG) extended monitoring; 41-60 minutes
95813	Electroencephalogram (EEG) extended monitoring; greater than 1 hour
95816	Electroencephalogram (EEG); including recording awake and drowsy
95819	Electroencephalogram (EEG); including recording awake and asleep
95925	Evoked potential studies
95926	Short latency somatosensory evoked potential study stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs

CLINICAL POLICY
Attention Deficit Hyperactivity Disorder

CPT® Codes	Description
95927	Short latency somatosensory evoked potential study stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in the trunk or head
95928	Central motor evoked potential study (transcranial motor stimulation); upper limbs
95929	Central motor evoked potential study (transcranial motor stimulation); lower limbs
95930	Visual evoked potential (VEP) testing central nervous system, checkerboard or flash
95933	Orbicularis oculi (blink) reflex, by electrodiagnostic testing
95937	Neuromuscular junction testing (repetitive stimulation paired stimuli), each nerve, any 1 method
95938	Short latency somatosensory evoked potential study stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs
95939	Central motor evoked potential study (transcranial motor stimulation);in upper and lower limbs
96101	Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI, Rorschach, WAIS), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report
96102	Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI and WAIS), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face
96103	Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI), administered by a computer, with qualified health care professional interpretation and report
96116	Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist's or physician's time, both face-to-face time with the patient and time interpreting test results and preparing the report
96118	Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report
96119	Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face

CLINICAL POLICY
Attention Deficit Hyperactivity Disorder

CPT® Codes	Description
96120	Neuropsychological testing (eg, Wisconsin Card Sorting Test), administered by a computer, with qualified health care professional interpretation and report
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour
96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion, up to 1 hour
97530	Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes
97532	Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes
97533	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes
97535	Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes
97750	Physical performance test or measurement (eg, musculoskeletal, functional capacity), with written report, each 15 minutes
97810	Acupuncture, one or more needles, w/o electric stimulation; initial 15 minutes of personal one-one contact with the patient.
97811	Acupuncture, one or more needles, w/o electric stimulation; each additional 15 minutes of personal one-one contact with the patient with re-insertion of needles.
97813	Acupuncture, one or more needles, with electric stimulation; initial 15 minutes of personal one-one contact with the patient.
97814	Acupuncture, one or more needles, with electric stimulation; each additional 15 minutes of personal one-one contact with the patient, with re-insertion of the needle(s).
98940	Chiropractic manipulative treatment (CMT); spinal, 1-2 regions
98941	Chiropractic manipulative treatment (CMT); spinal, 3-4 regions
98942	Chiropractic manipulative treatment (CMT); spinal, 5 regions
98943	Chiropractic manipulative treatment (CMT); extraspinal, 1 or more Regions

HCPCS codes considered not medically necessary when billed with a sole diagnosis of ADHD

HCPCS Codes	Description
P2031	Hair analysis (excluding arsenic)

CLINICAL POLICY
Attention Deficit Hyperactivity Disorder

HCPCS Codes	Description
S8040	Topographic brain mapping

ICD-10-CM Diagnosis Codes that Support Medical Necessity

ICD-10-CM Code	Description
F90.0 – F90.9	Attention-deficit hyperactivity disorders

Reviews, Revisions, and Approvals	Date	Approval Date
Policy developed.	08/16	08/16
Added 92540, 92545, 92548, 97535, 97750 as not medically necessary per Texas Medicaid Guidelines	12/16	
References reviewed and updated	07/17	08/17

References

1. Post, Robert E., and Stuart L. Kurlansik. "Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults." *American family physician* 85.9 (2012).
2. Bukstein O. "Attention deficit hyperactivity disorder: Epidemiology, pathogenesis, clinical features, course assessment, and diagnosis. In: UpToDate Hermann R. (Ed), UpToDate, Waltham, MA. Accessed on July 26, 2017.
3. Krull KR. "Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis." In: UpToDate. Torchia MM. (Ed), UpToDate, Waltham, MA. Accessed on July 26, 2017.
4. ATTENTION-DEFICIT, SUBCOMMITTEE ON. "ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents." *Pediatrics* (2011): peds-2011.
5. Gibbins, Christopher, and Margaret Weiss. "Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults." *Current psychiatry reports* 9.5 (2007): 420-426.
6. Chan, Eugenia, Jason M. Fogler, and Paul G. Hammerness. "Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review." *JAMA* 315.18 (2016): 1997-2008.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health

CLINICAL POLICY

Attention Deficit Hyperactivity Disorder

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

CLINICAL POLICY
Attention Deficit Hyperactivity Disorder



©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.